Add Glucokinase Activator to Target A1c

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.
Epistemonikos ID: 6fdc5db599672e7e4a8866afba68c844f64a5a9d
First added on: May 12, 2024